A New Look, New Direction for Society of Nuclear Medicine

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 8
Volume 11
Issue 8

LOS ANGELES-The Society of Nuclear Medicine (SNM) has changed its logo for the first time in its 49-year history. The new logo is designed to create a bright, fresh look for SNM, Alan Maurer, MD, said at the Society’s 49th Annual Meeting. Dr. Maurer, director of nuclear medicine, Temple University, is the immediate past president of the SNM.

LOS ANGELES—The Society of Nuclear Medicine (SNM) has changed its logo forthe first time in its 49-year history. The new logo is designed to create abright, fresh look for SNM, Alan Maurer, MD, said at the Society’s 49th AnnualMeeting. Dr. Maurer, director of nuclear medicine, Temple University, is theimmediate past president of the SNM.

The new logo retains the roots and heritage of SNM by keeping the atomic orbital symbol. A tagline in the new logo, "advancing molecular imaging," is seen emerging from the atomic orbital. It replaces the caduceus holding the atomic orbital in the old logo.

Although molecular imaging has always been an important part of nuclear medicine, the new tagline identifies the organization as being on the cutting edge of molecular imaging technology, said Michael Gelfand, MD, the new SNM president. "The new logo represents a first step in creating a new and evolving identity for SNM," he said. 

Recent Videos
A new partnership agreement involving AI use may help spread radiotherapeutic standards from academic centers to more patients in community-based practices.
For example, you have a belt of certain diseases or genetic disorders that you come across, such as sickle cell disease or thalassemia, that are more prevalent in these areas.
Recent findings presented at ASTRO 2025 suggest an “exciting opportunity” to expand the role of radiation oncology in different non-malignant indications.
The 3 most likely directions of radiotherapy advancements come from new technology, combinations with immunotherapy, and the incorporation of particle therapy.
Talent shortages in the manufacturing and administration of cellular therapies are problems that must be addressed at the level of each country.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
4 experts in this video
4 experts in this video